Last reviewed · How we verify

Allogeneic T cell progenitors, cultured ex-vivo

Smart Immune SAS · Phase 1 active Biologic Quality 0/100

Allogeneic T cell progenitors, cultured ex-vivo is a Biologic drug developed by Smart Immune SAS. It is currently in Phase 1 development. Also known as: SMART101.

At a glance

Generic nameAllogeneic T cell progenitors, cultured ex-vivo
Also known asSMART101
SponsorSmart Immune SAS
ModalityBiologic
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Allogeneic T cell progenitors, cultured ex-vivo

What is Allogeneic T cell progenitors, cultured ex-vivo?

Allogeneic T cell progenitors, cultured ex-vivo is a Biologic drug developed by Smart Immune SAS.

Who makes Allogeneic T cell progenitors, cultured ex-vivo?

Allogeneic T cell progenitors, cultured ex-vivo is developed by Smart Immune SAS (see full Smart Immune SAS pipeline at /company/smart-immune-sas).

Is Allogeneic T cell progenitors, cultured ex-vivo also known as anything else?

Allogeneic T cell progenitors, cultured ex-vivo is also known as SMART101.

What development phase is Allogeneic T cell progenitors, cultured ex-vivo in?

Allogeneic T cell progenitors, cultured ex-vivo is in Phase 1.

Related